

# pSELECT-neo-LacZ

A LacZ-expression plasmid selectable with Kanamycin/G418

Catalog code: psetn-lacz

<https://www.invivogen.com/pselect-neo>

For research use only

Version 19L13-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of pSELECT-neo-LacZ plasmid provided as lyophilized DNA

### Storage and stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable for at least 1 year at -20°C.

### Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

## GENERAL PRODUCT USE

pSELECT plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfecants and offer a variety of selectable markers. pSELECT plasmids contain two expression cassettes: the first drives the expression of the gene of interest and the second drives the expression of a large choice of dominant selectable markers for both *E. coli* and mammalian cells. They are both terminating with a strong polyadenylation signal (polyA) that separates the two expression cassettes thus preventing any transcription interference. The late SV40 polyA terminates the transcription of the gene of interest while the human β-globin polyA terminates the transcription of the selectable marker.

pSELECT-LacZ plasmids can be used as control vectors or for cloning of an open reading frame, as the LacZ gene is flanked by two unique restriction sites: Nco I at the 5' end that encompasses the Start codon and Nhe I at the 3'end.

## PLASMID FEATURES

### First expression cassette

- hEF1-HTLV prom is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter<sup>1</sup> and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat<sup>2</sup>. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.

• **LacZ:** The *E. coli* lacZ gene codes for the enzyme β-galactosidase which catalyzes the hydrolysis of the substrate X-Gal to produce a blue color that is easily visualized under a microscope.

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>3</sup>.

• **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

### Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Neo:** The neo gene from Tn5 confers resistance to Kanamycin in *E. coli* and G418 in mammalian cells. The neo gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.
- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription<sup>4</sup>.

1. Kim D.W. et al., 1990. Use of human elongation factor 1 alpha promoter as a versatile and efficient expression system. *Gene*, 91(2):217-23.
2. Takebe, Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell Biol.* 1: 466-472.
3. Carswell, S., & Alwine, J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
4. Yu J. & Russell J.E., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Bacterial antibiotic selection

Kanamycin (not provided) is normally used for *E. coli* at a final concentration of 50 µg/ml in liquid or solid media.

### Mammalian antibiotic selection

G418 is normally used at a concentration of 400 µg/ml. However, the optimal concentration needs to be determined for your cells.

## RELATED PRODUCTS

Product	Description	Cat. Code
ChemiComp GT116 cells G418	Competent <i>E. coli</i> cells Selection antibiotic	gt116-11 ant-gn-1

## TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873


InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com





**NotI (2)**1 **GC**GGCCGAATAAAATCTTATTTCATTACATGTGTGTTGGTTTGTAATCGTAACATACTGCCATCAAAACAAAAGAAACA**SgfI (176)**

101 AAACAAACTAGCAAAATAGGCTGCCAGTGCAGGTGCCAGAACATTCTCATCGAAGGATCTGCATCGCTCCGGTCCCAGCAGTGGCA

201 GAGCGCACATCGCCACAGTCCCAGAGAAGTTGGGGAGGGTGGCAATTGAACGGGTGCCTAGAGAAGGGCGGGTAAACTGGAAAGTGATG

301 TCGTGTACTGGCTCCGCCCTTTCCCAGGGTGGGGAGAACGTATATAAGTCAGTAGTCGCCGTGACGTTCTTCGCAACGGTTGCCAG

**HindIII (411)**

401 AACACAGCTGAAGCTCGAGGGCTCGATCTCTCCTCACGCGCCGCCCTACCTGAGGCCATCCAGCCGGTGAGTCGCGTTCTGCCCT

501 CCCGCCTGTTGCTCTCGAACACTCGCTGCCGCTAGGTAAGTTAAAGCTCAGGTGAGACCGGGCTTGTCCGGCTCCCTGGAGCCTACCTA

601 GACTCAGCCGGCTCCACGCTTGCCCTGACCTGCTCAACTCTACGTCTTGTTCGTTCTGCGCCGTTACAGATCCAAGCTGTGACC

**NcoI (726)****AgeI (718)**701 **G**GCCTACCTGAGATCaccgtcacATGGACCCCTTTGTGCTGCAAAGGAGAGACTGGAGAACCCCTGGAGTGACCCAGCTAACAGACTGGCTGCC

801 ACCCTCCCTTGCCCTTGAGGAACCTCTGAGGAAGCCAGGACAGACAGGCCAGCCAGCAGTCAGGTCTCTCAATGGAGAGTGGAGGTTGCTGGTT

25▶ i sProProPheAl aSer TrpArgAsnSer Gl uGl uAl aArgThrAspArgProSer Gl nGl nLeuArgSerLeuAsnGl yGl uTrpArgPheAl aTrpPh

901 CCCCTCCCTGAAGCTGTGCTGAGCTTGCGTGGAGTGACCTCCAGAGGCTGACACTGTTGTTGCCCCAGCACTGGCAGATGCATGGCTATGAT

58▶ eProAl aProGl uAl aVal ProGl uSer TrpLeuGl uCysAspLeuProGl uAl aAspThr Val Val Val ProSerAsnTrpGl nMetHi sGl yTyrAsp

1001 GCCCCCATCTACACCAATGTCACCTACCCCATCACTGTGAACCCCCCTTTGTGCCACTGAGAACCCCACTGGCTGCTACAGCCTGACCTCAATGTTG  
92▶ Al aProLleTyrThrAsnValThr TyrProLleThrValAsnProProPheValProThrGl uAsnProThrGl yCysTyrSerLeuThrPheAsnValA1101 ATGAGAGCTGGCTGCAAGAAGGCCAGACAGATCATTTGTGAGTGACTCTGCTCCACCTCTGGTCAATGGCAGGTGGGTTGGCTATGGCCA  
125▶ spGl uSer TrpLeuGl nGl uGl yGl nThrArg l l ePheAspGl yVal AsnSerAl aPheHi sLeuTrpCysAsnGl yArgTrpValGl yTyrGl yGl

1201 AGACACGGCAGGCTCCCTCTGAGTTGACTCTCTCAGAGCTGGAGGAACAGGCTGCTGATGGCTCAGGGTCTGATGGCTAGTGGCAGCTAC

158▶ nAspSerArgLeuProSerAl uPheAspLeuSerAl aPheLeuArgAl aGl yGl uAsnArgLeuAl aVal MetVal LeuArgTrpSerAspGl ySer Tyr

1301 CTGGAAAGCCAAAGCATGTGGAGGATCTGGCATCTCAGGGATGTGAGCTGACAAAGGCCACCCAGATTCTGACTTCCATGTTGCCACCA  
192▶ LeuGl uAspGl nAspMetTrpArgMetSerGl y l l ePheArgAspVal Ser LeuLeuHi sLysProThrThrGl n l l eSerAspPheHi sValAl aThrA1401 GTTCAATGATGACTTCAGCAGAGCTGGCTGAGGTGAGATGTTGAGAGACTCACCTGAGAGTCACAGTGCAGCTCTGGCAAGG  
225▶ r gPheAsnAspAspPheSer ArgAl aVal LeuGl uAl aGl uVal Gl nMetTcysGl yGl uLeuArgAspTyrLeuArgVal Thr Val Ser LeuTrpGl nGl1501 TGAGACCCAGGTGGCCTCTGCACAGCCCCCTTGAGGAGAGATATTGATGAGAGAGGAGCTATGCTGACAGAGTCACCTGAGGCTCAATGTTGAG  
258▶ yGl uThrGl nValAl aSer Gl yThrAl aProPheGl yGl uGl l l eAspGl uArgGl yGl yTyrAl aAspArgVal ThreLeuArgLeuAsnValGl u1601 AACCCAAAGCTGGCTGAGATCCCCAACCTCTACAGGGCTTGTGGAGCTGCAACTGCTGATGGCACCTCTGATTGAGCTGAAGGCTGTGATG  
292▶ AsnProLsLeuTrpSerAl aGl u l l eProAsnLeuTyrArgAl aVal Val Gl uLeuHi sThrLeu l l eGl uAl aGl uAl aCysAspV1701 TTGGATTAGAGAAGTCAGGATTGAGAATGCCCTGCTGCTCATGGCAAGCCTGCTCATGGGAGTCAACAGGCATGAGCACCCCTCTGCA  
325▶ al Gl yPheArgGl uValArg l l eGl uAsnGl yLeuLeuLeuAsnGl yLysProLeuLeu l l eArgGl yVal AsnArgHi sGl uHi sHi sP roLeuHi**EcoRV (1837)****XmnI (1859)**1801 TGGACAAGTGTGGATGAAACAGACAATGGTCAAGATATCTGCTATGAAGCAGAACAACTTCATGCTCAGGTGCTCACTACCCCAACCCCT  
358▶ sGl yGl nValMetAspGl uGl nThrMetValGl nAsp l l eLeuLeuMetLysGl nAsnAsnPheAsnAl aVal ArgCysSerHi sTyrProAsnHi sPro1901 CTCTGGTACACCCCTGTGAGCAGGTATGGCTGTATGGTGTGAGCAACATTGACACATGGCATGGCCATGACAGGCTCACAGATGAC  
392▶ LeuTrpThrLeuCysAspArgTyrGl yLeuTyrValValAspGl uAl aAsnAl l l eGl uThrHi sGl yMetValProMetAsnArgLeuThrAspAspP2001 CCAGGGCTGCTCCATGTCAGAGATGGCAGGATGTCAGAGAGCAGAACCCCCCTCTGATGGCATCTGGCAATGAGTCAGTGGCT  
425▶ r oArgTrpLeuProAl aMetSerGl uArgValThrArgMetValGl nArgAspArgAsnHi sProSerVal l l l eTrpSerLeuGl yAsnGl uSerGl2101 ACATGGAGCCAACCATGATGCTCTCACGGTGGATCAAGTCTGACCCCAGCAGACCTGTGAGTGAAGGAGGTTGAGCAGACACCACAGCCACA  
458▶ yHi sGl yAl aAsnHi sAspAl aLeuTyrArgTrp l l eLysSerValAspProSerArgProValGl nTyrGl uGl yGl yAl aAspThrThrAl aThr2201 GACATCATCTGCCCATGATGCCAGGGTGTGAGGACCAGCCCTCCCTGCTGTGCCCCAAGTGGAGCATCAAGAAGTGGCTCTCTGCTCTGGAGAGA  
492▶ Asp l l l eCysProMetTyrAl aArgValAspGl uAspGl nProPheProAl aVal ProLysTrpSer l l eLysLysTrpLeuSerLeuProGl yGl uT2301 CCAGACCTCTGATCTGTGAAATGACATGCAATGGCAACTCTCTGGGAGGCTTGCAGAGTACTGGCAAGCTTCAGACAGTACCCAGGCTGCA  
525▶ hrArgProLeu l l eLeuCysGl uTyrAl aHi sAl aMetGl yAsnSerLeuGl yGl yPheAl aLysTyrTrpGl nAl aPheArgGl nTyrProArgLeuGl2401 AGGAGGATTGTGGGACTGGTGGACCAATCTCATCAAGTATGAGAATGGCAACCCCTGGCTGCCTATGGAGGAGCTTGGTGAACCCCC  
558▶ nGl yGl yPheValTrpAspTrpValAspGl nSerLeu l l eLysTyrAspGl uAsnGl yAsnProTrpSerAl aTyrGl yGl yAspPheGl yAspThrPro2501 AATGACAGGCAGTCTGCATGAATGGCTGGTTGCAGACAGGACCCCTCACCCCTGCCCTCACAGAGGCAACAGCACAGTTCTCAGTTCA  
592▶ AsnAspArgGl nPheCysMetAsnGl yLeuValPheAl aAspArgThrProHi sProAl aLeuThrGl uAl aLysHi sGl nGl nGl nPhePheGl nPheA2601 GGCTGCTGGACAGACCATGGGTGACATCTGAGTACCTCTCAGGCACTCTGACAATGAGCTCTGCACTGGATGGTGCCTGGATGGCAAGCCTCT  
625▶ r gLeuSerGl yGl nThr l l eGl uVal l l eTyrThrSerGl uTyrLeuPheArgHi sSerAspAsnGl uLeuLeuHi sTrpMetValAl aLeuAspGl yLysProLe2701 GGCTCTGGTGGGCTCTGGATGTGGCCCTCAAGGAAACAGCTGATTGAGACTGCTGCAGCTGCCCTCACAGAGCTCTGCTGGACAACACTGTC  
658▶ uAl aSerGl yGl uValProLeuAspValAl aProGl nLysGl yLeu l l eGl uLeuProGl uLeuProGl nProGl uSerAl aGl yGl nLeuTrpLeu2801 ACAGTGAGGGTGGTCAAGCCATGCAACAGCTTGTCTGAGGCCACATCTCTGCATGGCAGCAGTGGAGGCTGGCTGAGAACCTCTGTGACCC  
692▶ ThrValArgValValGl nProAsnAl aThrAl aTrpSerGl uAl aGl yHi s l l eSerAl aTrpGl nGl nTrpArgLeuAl aGl uAsnLeuSerValThrL2901 TGCCTGCTGCCCTCATGCCATCCCTCACCTGACAACATCTGAAATGGACTCTGCTATTGAGCTGGCAACAAGAGATGGCAGTTCAACAGGCAGTCTGG  
725▶ euProAl aAl aSerHi sAl l l eProRoHi sLeuThrThrSerGl uMetAspPheCys l l eGl uLeuGl yAsnLysArgTrpGl nPheAsnArgGl nSerGl3001 CTTCTGCTCAGATGGATTGGAGACAAGAAGCAGCTCCACCCCTCAGGGACCAATTCACTACCCAGGGCTCTGGACAATGACATTGGAGTGTCT  
758▶ yPheLeuSerGl nMetTrp l l eGl yAspLysLysGl nLeuLeuThrProLeuArgAspGl nPheThrArgAl aProLeuAspAsn l l eGl yValSer3101 GAGGCCACAGGATTGACCCAAATGCTGGGTGGAGAGGTGGAAGGCTGCTGGACACTACCCAGGCTGAGGGCTGCCCTGCTCAGTGCACAGCAGACACCC  
792▶ Gl uAl aThrArg l l eAspProAsnAl aTrpValGl uArgTrpLysAl aAl aGl yHi sTyrGl nAl aGl uAl aAl aLeuLeuGl nCysThrAl aAspThrL3201 TGGCTGATGCTGTTGATCACACAGCCATGCTGGCAGCACCAAGGCAAGACCCCTGTTCATCAGCAGAAAGACCTACAGGATTGATGGCTTGGGACA  
825▶ euAl aAspAl aValLeu l l eThrThrAl aHi sAl aTrpGl nHi sGl yLysThrLeuPhe l l eSerArgLysThrTyrArg l l eAspGl ySerGl yGl3301 GATGGCAATCACAGTGGATGGAGGCTCTGACACACCTCACCTGCAAGGATTTGGCCTGACTGTCACTGGCACAGGTGGCTGAGGGTGAAC  
858▶ nMetAl a l l eThrValAspValGl uValAl aSerAspThrProHi sProAl aArg l l eGl yLeuAsnCysGl nLeuAl aGl uAl aGl uArgValAsn3401 TGGCTGGGCTTAGGCCCTCAGGAGAACATCCCTGACAGGCTGACAGCTGCTGGTGGACAGGTGGGACCTGCCCTGCTGACATGTCACACCCCTATG  
892▶ TrpLeuGl yLeuGl yProGl uAsnTyrProAspArgLeuThrAl aAl aCysPheAspArgTrpLeuAspLeuSerAspMetTyrThrProTrpV3501 TGTGCTCTGAGAATGGCTGAGGTGTCGACCAAGGGAGCTGAACATGGTCTCACAGTGGAGGGAGACTTCAACATCTCAGGTACTC  
925▶ aPheProSerGl uAsnGl yLeuArgCysGl yThrArgGl uLeuAsnTyrGl yProHi sGl nTrpArgGl yAspPheGl nPheAsn l l eSerArgTyrSe

